TY - JOUR
T1 - Superparamagnetic iron oxide nanoparticles for delivery of tissue plasminogen activator
AU - Chen, Jyh Ping
AU - Yang, Pei Chin
AU - Ma, Yunn Hwa
AU - Lu, Yu Jen
PY - 2011
Y1 - 2011
N2 - Magnetic nanoparticle (MNP) modified by carboxymethyl dextran (CMD) was synthesized and characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, superconducting quantum interference device, dynamic light-scattering, thermogravimetric analysis, and X-ray diffraction. CMD coating on the particle surface provides abundant-COOH functional groups for conjugating with a thrombolytic drug, recombinant tissue plasminogen activator (rtPA). CMDcoated MNP (CMD-MNP) prepared with higher CMD/MNP ratios had higher CMD content, less iron content, more-COOH surface groups, smaller hydrodynamic diameter, and smaller saturation magnetization. The in vitro biocompatibility study using lactate dehydrogenase assays indicated that CMD-MNP elicited no cell cytotoxicity. The optimum drug loading could be achieved by contacting 0.25 mg rtPA with 5 mg CMD-MNP where all rtPA is immobilized to the magnetic nanocarrier with full retention of its thrombolytic activity.
AB - Magnetic nanoparticle (MNP) modified by carboxymethyl dextran (CMD) was synthesized and characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, superconducting quantum interference device, dynamic light-scattering, thermogravimetric analysis, and X-ray diffraction. CMD coating on the particle surface provides abundant-COOH functional groups for conjugating with a thrombolytic drug, recombinant tissue plasminogen activator (rtPA). CMDcoated MNP (CMD-MNP) prepared with higher CMD/MNP ratios had higher CMD content, less iron content, more-COOH surface groups, smaller hydrodynamic diameter, and smaller saturation magnetization. The in vitro biocompatibility study using lactate dehydrogenase assays indicated that CMD-MNP elicited no cell cytotoxicity. The optimum drug loading could be achieved by contacting 0.25 mg rtPA with 5 mg CMD-MNP where all rtPA is immobilized to the magnetic nanocarrier with full retention of its thrombolytic activity.
KW - Dextran
KW - Drug delivery
KW - Magnetic nanoparticles
KW - Thrombolysis
KW - Tissue plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=84857185272&partnerID=8YFLogxK
U2 - 10.1166/jnn.2011.3953
DO - 10.1166/jnn.2011.3953
M3 - 文章
C2 - 22409062
AN - SCOPUS:84857185272
SN - 1533-4880
VL - 11
SP - 11089
EP - 11094
JO - Journal of Nanoscience and Nanotechnology
JF - Journal of Nanoscience and Nanotechnology
IS - 12
ER -